Company: PACB
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001299130-25-000168
Chunk: 60

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 60
---
 to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities.

Q3 Fiscal 2025 Form 10-Q9

Assets and Liabilities Measured at Fair Value on a Recurring BasisThe following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis: September 30, 2025December 31, 2024(In thousands)Level 1Level 2Level 3TotalLevel 1Level 2Level 3TotalAssetsCash and cash equivalents $52,483 $3,984 $— $56,467 $55,370 $— $— $55,370 Investments:Corporate debt securities — 23,420 — 23,420 — 46,905 — 46,905 U.S. government & agency securities— 218,767 — 218,767 — 287,656 — 287,656 Total investments — 242,187 — 242,187 — 334,561 — 334,561 Short-term restricted cash300 — — 300 690 — — 690 Long-term restricted cash1,532 — — 1,532 1,532 — — 1,532 Total assets measured at fair value $54,315 $246,171 $— $300,486 $57,592 $334,561 $— $392,153 LiabilitiesContingent consideration$— $— $— $— $— $— $18,700 $18,700 Total liabilities measured at fair value $— $— $— $— $— $— $18,700 $18,700 During the nine months ended September 30, 2025, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis, and our valuation techniques did not change compared to the prior year.Contingent ConsiderationIn connection with the August 2023 Apton Biosystems, Inc. (“Apton”) acquisition, contingent consideration of $